VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 8, 2008) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, confirmed today that its 2008 milestones include results from three Phase II human clinical trials that will indicate whether the Company's drugs AL-108 and AL-208 have an effect on three of the most underserved diseases - Alzheimer's disease (AD), stroke and cognitive impairment associated with schizophrenia.
